The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
 
Nazli Dizman
Consulting or Advisory Role - Vivreon Biosciences
 
Ameish Govindarajan
No Relationships to Disclose
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Luis A Meza
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Elyse H. Chan
No Relationships to Disclose
 
Kyle O. Lee
No Relationships to Disclose
 
Sweta R. Prajapati
No Relationships to Disclose
 
Matthew I. Feng
No Relationships to Disclose
 
Vivian Loo
No Relationships to Disclose
 
Makala Pace
No Relationships to Disclose
 
Shea O'brien
No Relationships to Disclose
 
Erin B. Bailey
No Relationships to Disclose
 
Regina Barragan-Carrillo
No Relationships to Disclose
 
Alex Chehrazi-Raffle
No Relationships to Disclose
 
Xiaochen Li
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Sumanta Monty Pal
Research Funding - Allogene Therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Roche